Loading patent…
AssigneeAxceso Biopharma Co., Ltd.
InventorMyeong Jun CHOI
Estimating the term…
Disclosed in the present invention are a use as an immune enhancer of phytosphingosine-1-phosphate (P1P), O-cyclic P1P (cP1P), N-acetylphytosphingosine-1-phosphate (NAPS-1-P), and pharmaceutically acceptable salts thereof, and a pharmaceutical composition or vaccine for treating dementia, comprising such substance on the basis of a neuronal cell death inhibitory effect. The substance according to the present invention exhibits an effect of enhancing Th2 immune response and inhibiting Th1 immune response and has an effect of protecting neurons as well, and thus can be useful as an immune enhancer to help the production of antibodies for the development of a dementia vaccine, as well as an agent for preventing or treating dementia.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method for preventing or treating dementia, or inhibiting neuronal cell death caused by oxidative stress or amyloid beta peptide in a subject in need thereof, comprising administering an effective amount of P1P (phytosphingosine-1-phosphate), cP1P (O-cyclic P1P) or NAPS-1-P (N-acetyl phytosphingosine-1-phosphate), or a pharmaceutically acceptable salt thereof to the subject.
A method for enhancing Th2 immune response and inhibiting Th1 immune response comprising treating nerve cells with P1P (phytosphingosine-1-phosphate), cP1P (O-cyclic P1P), or NAPS-1-P (N-acetyl phytosphingosine-1-phosphate), or a pharmaceutically acceptable salt thereof.
A method for inhibiting neuronal cell death caused by oxidative stress or amyloid beta peptide, comprising treating nerve cells with P1P (phytosphingosine-1-phosphate), cP1P (O-cyclic P1P) or NAPS-1-P (N-acetyl phytosphingosine-1-phosphate), or a pharmaceutically acceptable salt thereof.
(canceled)
(canceled)
Dependencies are inferred from the claim text.